Starpharma is proud to contribute to the scientific community through research and development of innovative technology and products, and publish our research widely to support commercialisation of our DEP® technology and products.
DEP® Platform
|
Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients with advanced solid tumors: a phase 1/2 trial
Presentation at the ASCO Annual Meeting 2024
|
Presentation at the ASCO Annual Meeting 2024 | View |
|
Efficacy and safety of dendrimer-enhanced cabazitaxel (DEP CTX) in patients with advanced solid cancers; a phase 1/2 trial
Presentation at the ASCO Annual Meeting 2024
|
Presentation at the ASCO Annual Meeting 2024 | View |
|
Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in advanced esophago-gastric cancers in a phase 1/2 trial
Poster presented at the ASCO Gastrointestinal (GI) Cancers Symposium 2024
|
Poster presented at the ASCO Gastrointestinal (GI) Cancers Symposium 2024 | View |
|
An SN38 dendrimer nanoparticle, DEP irinotecan (SN38-SPL9111), demonstrates efficacy in mouse models of gastrointestinal cancer and augments anti-tumor effects of immune checkpoint blockade and PARP inhibition
Poster presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
|
Poster presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 | View |
|
A HER2 targeted polylysine dendrimer nanoparticle radiotheranostic demonstrates excellent tumor accumulation, rapid clearance from circulation, and promising performance in PET-CT imaging
Poster presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
|
Poster presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 | View |
|
A phase 1/2 study of dendrimer-enhanced DEP SN38 (SN38/SPL9111/DEP irinotecan) in patients with advanced solid tumours
Poster presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
|
Poster presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 | View |
|
Efficacy and safety of dendrimer-enhanced (DEP®) cabazitaxel (CTX-SPL9111) in men with metastatic castration-resistant prostate cancer (mCRPC) in a phase 1/2 trial
Poster presented at the European Society of Medical Oncology (ESMO) Congress 2022
|
Poster presented at the European Society of Medical Oncology (ESMO) Congress 2022 | View |
|
A comparison of the pharmacokinetics and pulmonary lymphatic exposure of a generation 4 PEGylated dendrimer following intravenous and aerosol administration to rats and sheep
Pharmaceutical Research
|
Pharmaceutical Research | View |
|
Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous administration in rats
Molecular Pharmaceutics
|
Molecular Pharmaceutics | View |
|
Nano-chemotherapeutics: maximising lymphatic drug exposure to improve the treatment of lymph-metastatic cancers
Journal of Controlled Release
|
Journal of Controlled Release | View |
|
Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy
Journal of Controlled Release
|
Journal of Controlled Release | View |
|
Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung Is highly size-dependent
Molecular Pharmaceutics
|
Molecular Pharmaceutics | View |
|
PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin
Journal of Controlled Release
|
Journal of Controlled Release | View |
|
A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems
Nanomedicine: Nanotechnology, Biology and Medicine
|
Nanomedicine: Nanotechnology, Biology and Medicine | View |
|
Doxorubicin- conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models
Molecular Pharmaceutics
|
Molecular Pharmaceutics | View |
|
Association of chemotherapeutic drugs with dendrimer nanocarriers: an assessment of the merits of covalent conjugation compared to noncovalent encapsulation
Molecular Pharmaceutics
|
Molecular Pharmaceutics | View |
|
Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties
Nanomedicine
|
Nanomedicine | View |
|
Capping methotrexate α-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers
Molecular Pharmaceutics
|
Molecular Pharmaceutics | View |
|
Targeting the lymphatics using dendritic polymers (dendrimers)
Advanced Drug Delivery Reviews
|
Advanced Drug Delivery Reviews | View |
|
Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker
Journal of Controlled Release
|
Journal of Controlled Release | View |
|
PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats
Journal of Controlled Release
|
Journal of Controlled Release | View |
|
Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-L-lysine dendrimers
Molecular Pharmaceutics
|
Molecular Pharmaceutics | View |
|
Partly-PEGylated poly-L-lysine dendrimers have reduced plasma stability and circulation times compared with fully PEGylated dendrimers
Journal of Pharmaceutical Sciences
|
Journal of Pharmaceutical Sciences | View |
|
The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-Lysine dendrimers
Molecular Pharmaceutics
|
Molecular Pharmaceutics | View |
|
Impact of surface derivatization of poly-L-lysine dendrimers with anionic arylsulfonate or succinate groups on intravenous pharmacokinetics and disposition
Molecular Pharmaceutics
|
Molecular Pharmaceutics | View |
|
Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats
Molecular Pharmaceutics
|
Molecular Pharmaceutics | View |
|
Lymphatic transport and lymph node targeting of methotrexate-conjugated PEGylated dendrimers are enhanced by reducing the length of the drug linker or masking interactions with the injection site
Nanomedicine: Nanotechnology, Biology and Medicine
|
Nanomedicine: Nanotechnology, Biology and Medicine | View |
Anti-Infective Portfolio (SPL7013)
|
Astodrimer sodium nasal spray forms a barrier to SARS-CoV-2 in vitro and preserves normal mucociliary function in human nasal epithelium
Nature, Scientific Reports
|
Nature, Scientific Reports | View |
|
Astodrimer Sodium Nasal Spray versus Placebo in Non-Hospitalised Patients with COVID-19: A Randomised, Double-Blinded, Placebo-Controlled Trial
Pharmaceutics
|
Pharmaceutics | View |
|
Astodrimer sodium antiviral nasal spray for reducing respiratory infections is safe and well tolerated in a randomized controlled trial
Nature, Scientific Reports
|
Nature, Scientific Reports | View |
|
Utility of Astodrimer sodium 1% nasal spray for pandemic preparedness demonstrated by broad-spectrum antiviral effects and protection against SARS-CoV-2 omicron, and influenza A and B virus protection
Poster Presentation (RespiDART Conference, December 2022)
|
Poster Presentation (RespiDART Conference, December 2022) | View |
|
Effect of Astodrimer sodium against SARS-CoV-2 variants in vitro
Poster Presentation (Conference on Retroviruses and Opportunistic Infections [CROI] 2022)
|
Poster Presentation (Conference on Retroviruses and Opportunistic Infections [CROI] 2022) | View |
|
Protective effects of Astodrimer sodium 1% nasal spray formulation against SARS-CoV-2 nasal challenge in K18-hACE2 mice
Viruses
|
Viruses | View |
|
Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro
Antiviral Research
|
Antiviral Research | View |
|
Topical Astodrimer sodium, a non-toxic polyanionic dendrimer, demonstrates antiviral activity in an experimental ocular adenovirus infection model
Molecules
|
Molecules | View |
|
Astodrimer sodium and bacterial vaginosis: a mini review
Archives of Gynecology and Obstetrics
|
Archives of Gynecology and Obstetrics | View |
|
A phase 3, randomised, controlled trial of Astodrimer 1% Gel for preventing recurrent bacterial vaginosis
European Journal of Obstetrics & Gynecology and Reproductive Biology: X
|
European Journal of Obstetrics & Gynecology and Reproductive Biology: X | View |
|
Two phase 3, double-blinded, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis
European Journal of Obstetrics, Gynaecology and Reproductive Biology
|
European Journal of Obstetrics, Gynaecology and Reproductive Biology | View |
|
A phase 2, double-blinded, multicentre, randomised, placebo-controlled, dose-ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosis
PLoS One
|
PLoS One | View |
